The pediatric trial did not raise any safety concerns, the spokesperson said, but would be paused while the UK’s Medicines and Healthcare Regulators, or the MHRA, investigate rare cases of those with. There is a blood clot while having low blood platelet levels.
“Parents and children should attend all scheduled visits and be able to contact the trial site with any questions,” the spokesperson said.
When contacted by CNN, AstraZeneca will send questions to Oxford University.
Last week, the drug regulator said at least 30 people in the country received rare blood types after receiving the vaccine. But warned it was too early to know if the shot caused blood clots.
MHRA chief Dr. June Rain told CNN on Tuesday that the MHRA was “aware of the University of Oxford̵7;s decision to temporarily stop the use of the drug in trials …
“The safety of the participants in the clinical trial is our top priority and no safety concerns have been reported in this trial,” she added.
The MHRA said in a statement it had received 22 reports of intravenous thrombosis (CVST) in which blood clotting in the sinus drains blood from the brain, and eight more reported in the. The total number of 15.8 million received at least One vaccine by March 21
They did not say how many blood clots might be among the 15.8 million people.
The agency has recommended that the UK continue to carry out vaccinations in all groups, arguing that coagulation events are extremely rare and that the benefits still outweigh the risks, reflecting similar assessments by: European Medicines Agency (EMA) and the World Health Organization (WHO).
Other national regulators have reported the occurrence of blood clots in vaccinated people, especially in Europe where AstraZeneca vaccine is widely used. Some countries are choosing to withhold all vaccines, while others have restricted vaccines to certain age groups.
In general, blood clots are so common that a certain number of people are expected to pick them up for a variety of reasons on any given day of the week. If someone was vaccinated and had a blood clot, this doesn’t necessarily mean that the transfusion caused a clot.
After a preliminary report on coagulation last month, AstraZeneca quickly pointed out that the overall incidence of obstruction was lower in people who received the shot in the general population.
An AstraZeneca spokesman said in a statement to CNN last week: “Patient safety remains the company’s top priority” and pointed out that UK, EU and WHO recommendations apply.
“The benefit profile of the vaccine was re-confirmed in the EMA’s monthly safety update,” the spokesperson said.
CNN’s Angela Dewan and Richard Allen Greene contributed to this report.